The von Willebrand factor (VWF) is a clotting protein. Von Willebrand factor’s primary function is to bind to other proteins, in particular factor VIII, and is important in platelet adhesion to wound sites. Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF). Von Willebrand disease is a chronic bleeding disorder, wherein blood does not clot well. Most people with the disease are born with it; however, its warning signs may not show up for years. Some people may suspect they have a bleeding disorder when they have heavy bleeding after a dental procedure or, for women, during a menstrual period. The most common sign of von Willebrand disease is abnormal bleeding. The four types of von Willebrand disease are type 1 von Willebrand disease, type 2 von Willebrand disease, type 3 von Willebrand disease, and acquired von Willebrand disease. Von Willebrand disease (VWD) is the most common cause of menorrhagia in women. Moreover, von Willebrand disease is common in developed countries such as the U.S. and economies in Western Europe. Around 16% to 37% women with high menstrual bleeding are diagnosed with Von Willebrand disease (VWD) in these regions. Physicians recommend the following blood tests for diagnosis of von Willebrand disease: von Willebrand factor antigen test, ristocetin cofactor activity test, factor VIII clotting activity test, and von Willebrand factor multimers test.
The global von Willebrand disease treatment market can be segmented based on disease type, drug type, distribution channel, and region. In terms of disease type, the global market can be classified into type 1 von Willebrand disease, type 2 von Willebrand disease, type 3 von Willebrand disease, and acquired von Willebrand disease. Type 1 von Willebrand disease is the most common type and is projected to account for the major share of the global market. Based on drug type, the global von Willebrand disease treatment market can be classified into desmopressin, replacement therapies, contraceptives, clot-stabilizing medications, and others. The desmopressin segment is anticipated to account for major von Willebrand disease treatment market share, as these drugs are used for long-term treatment of the disease. In terms of distribution channel, the global von Willebrand disease treatment market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the global von Willebrand disease treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to account for the leading share of the global von Willebrand disease treatment market due to favorable reimbursement scenario and higher health care spending. Europe is likely to be the second largest market for von Willebrand disease treatment during the forecast period due to rise in awareness about new treatment options and developed regulatory framework. The von Willebrand disease treatment market in Asia Pacific is projected to grow at a rapid pace in the near future, driven by rise in prevalence of blood cloth diseases and improving health care infrastructure in the region.
Key players operating in the global von Willebrand disease treatment market are Octapharma AG, Grifols, S.A., Shire plc, Pfizer, Inc., Novo Nordisk A/S, Bayer AG, Sanofi, Kedrion S.p.A, and CSL Behring, among others. Expansion of product portfolio through mergers and acquisitions is a key strategy followed by these market players.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]